{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_176", "document_index": 23, "latency_s": 1.8348098999995273, "prompt_toks": 51660, "completion_toks": 89, "relevance_score": 0.000118667966}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    American Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2202\n\nWithdrawal symptoms may occur in patients receiving opiate agonists concomitantly with opiate antagonists (e.g., naloxone, naltrexone) or opiate partial agonists (e.g., buprenorphine, butorphanol, nalbuphine, pentazocine). Partial agonists should not be administered in patients receiving opiate agonists as they may reduce the analgesic effect and/or precipitate withdrawal symptoms. /Opiate agonists/\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2202\n\nFor more Interactions (Complete) data for CODEINE (17 total), please visit the HSDB record page.\n\n13.1.14 Antidote and Emergency Treatment\n\nEmergency and supportive measures: Maintain an open airway and assist ventilation if necessary. Administer supplemental oxygen. Treat coma, seizures, hypotension, and noncardiogenic pulmonary edema if they occur. /Opiates and opioids/\n\n\n                    Context: \n                    This excerpt provides critical information on opioid withdrawal symptoms and emergency treatment protocols, specifically for patients receiving opiate agonists in combination with antagonists like naloxone or partial agonists such as buprenorphine. It is relevant for understanding drug interactions and overdose management within the comprehensive chemical safety and pharmacology data presented in the full document. Key details include the risk of precipitating withdrawal and recommended supportive measures like airway management and oxygen therapy.\n                "}
{"metadata": {"source": "erowid", "title": "Erowid Buprenorphine (Temgesic, Subutex) Vault", "description": "Information about Buprenorphine (Temgesic, Subutex) including uses, images, and links to other resources.", "language": "No language found.", "url": "https://www.erowid.org/pharms/buprenorphine/buprenorphine.shtml", "drug": "Buprenorphine", "cid": 644073, "substance": "buprenorphine", "category": "PHARMS", "erowid_column": "MainPage", "char_count": 6146, "word_count": 850, "doc_id": "doc_107", "num_chunks": 8, "chunk_id": "107::chunk_6", "document_index": 107, "latency_s": 0.5684546000120463, "prompt_toks": 2109, "completion_toks": 64, "relevance_score": 0.00010310212}, "content": "Drug: Buprenorphine | cid: 644073\nSource: erowid | Source description: Information about Buprenorphine (Temgesic, Subutex) including uses, images, and links to other resources.\nErowid name: buprenorphine\nCategory: PHARMS\nField: MainPage\n\n                    Text: \n                    ADDICTION & TREATMENT #\n\nFDA approves first buprenorphine implant [...] - FDA News Release, May 26 2016\n\nBuprenorphine Proves Effective Treatment for Heroin Addiction - NIDA Notes\n\nBuprenorphine Drug Detox - Information and list of Physicians and Treatment Centers\n\nSo You Thought You Could Get Off Suboxone? - The Fix.com, Sep 4, 2014\n\nMEDIA COVERAGE #\n\nThe New York Times is dead wrong about drug addiction - Dec 22, 2013, salon.com\n\nAddiction Treatment With a Dark Side - Nov 16, 2013, NYTimes\n\nPharma Gamesmanship in the Booming Business of Addiction Therapeutics: the Case of Suboxone - Mar 2013, efcannon\n\nCongress increases doctors' ability to prescribe buprenorphine for opiod addiction, Dec 2006, PRNewswire\n\nCity moves to expand drug treatment access, Oct 4 2006, baltimoresun.com\n\nPer-doctor prescription caps limit treatment of addicts, Jun 12 2006, Post-Gazette.com\n\nNew drug treats the new face of addiction - USA Today, Jan 24 2006\n\n\n                    Context: \n                    This chunk provides information on addiction treatment and media coverage related to buprenorphine, highlighting FDA approvals, effectiveness for heroin addiction, detox resources, treatment access, and notable news articles from 2006 to 2016, making it relevant for understanding buprenorphine’s role in therapy and public discourse.\n                "}
{"metadata": {"source": "psychonaut", "title": "Methadone - PsychonautWiki", "description": "Methadone (sold under trade names such as Dolophine and Methadose) is a synthetic opioid analgesic used for the treatment of moderate to severe pain and for the treatment of opioid addiction. It is commonly used to treat and manage the symptoms of opioid addiction. The subjective effects are similar to those of other synthetic opioids such as fentanyl, however, most users note a significantly stronger euphoria. Like dextropropoxyphene, the use of methadone is associated with cardiac arrhythmia, however it is more common with dextropropoxyphene than it is with methadone.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/Methadone", "drug": "Methadone", "cid": 4095, "char_count": 21869, "word_count": 3171, "doc_id": "doc_87", "num_chunks": 31, "chunk_id": "87::chunk_16", "document_index": 87, "latency_s": 0.4900250000064261, "prompt_toks": 5585, "completion_toks": 38, "relevance_score": 2.5268228e-05}, "content": "Drug: Methadone | cid: 4095\nSource: psychonaut | Source description: Methadone (sold under trade names such as Dolophine and Methadose) is a synthetic opioid analgesic used for the treatment of moderate to severe pain and for the treatment of opioid addiction. It is commonly used to treat and manage the symptoms of opioid addiction. The subjective effects are similar to those of other synthetic opioids such as fentanyl, however, most users note a significantly stronger euphoria. Like dextropropoxyphene, the use of methadone is associated with cardiac arrhythmia, however it is more common with dextropropoxyphene than it is with methadone.\n\n                    Text: \n                    It is strongly recommended that one use harm reduction practices when using this drug.\n\nTolerance and addiction potential\n\nAs with other opioids, the chronic use of methadone can be considered extremely addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal symptoms may occur if a person suddenly stops their usage.\n\n\n                    Context: \n                    This excerpt discusses harm reduction advice and the high risk of dependence associated with methadone, emphasizing the need for cautious use due to its addictive potential and withdrawal risks highlighted later in the document.\n                "}
